| | Univariate | Multivariate |
|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value |
|---|
| Treatment intervala |
| Group 1 | 1 (reference) | | | |
| Group 2 | 0.772 (0.405–1.472) | 0.433 | | |
| Age |
| < 65 yr | 1 (reference) | | | |
| ≥ 65 yr | 0.202 (0.028–1.479) | 0.115 | | |
| CA-125 |
| < 40 U/mL | 1 (reference) | | 1 (reference) | |
| ≥ 40 U/mL | 2.664 (1.401–5.065) | 0.003 | 1.930 (0.997–3.776) | 0.054 |
| Histology |
| Serous | 1 (reference) | | | |
| Non-serous | 1.820 (0.900–3.682) | 0.096 | | |
| Surgery |
| Laparoscopy | 1 (reference) | | 1 (reference) | |
| Laparotomy | 3.060 (1.081–8.661) | 0.035 | 2.572 (0.889–7.438) | 0.081 |
| ASA scoreb |
| 1 | 1 (reference) | | | |
| 2, 3 | 1.057 (0.484–2.310) | 0.889 | | |
| Residual diseasec |
| R0 | 1 (reference) | | 1 (reference) | |
| R1, R2 | 3.699 (1.929–7.093) | < 0.001 | 3.018 (1.486–6.130) | 0.002 |
| Platinum free interval |
| 6-12mo | 1 (reference) | | 1 (reference) | |
| over 12mo | 0.462 (0.224–0.954) | 0.037 | 0.398 (0.180–0.880) | 0.023 |
| Recurrence no. |
| 1st recur | 1 (reference) | | | |
| 2nd recur | 1.277 (0.451–3.619) | 0.645 | | |
- aEnrolled patients were divided into two groups; Group1 (treatment interval ≤ 10 days) and Group2 (treatment interval > 10 days)
- bASA score, American Society of Anaesthesiologists score
- cThe level of residual disease after SCS was divided into no gross (R0), 1–9 mm (R1), and equal to or more than 10 mm residual disease (R2)
